CCR4 and cancer: Various other DT-based immunotoxins have also been studied, which are specifically targeted to cancers of interest, including cell-penetrating peptide BR2 and receptor of Treg cells, CCR4 [102], DT386-BR2 [103], and DT-anti-CCR4 [104].